26 Jun 2020
Controversies in antiplatelet therapy for secondary prevention of coronary artery events
Sponsored by AstraZeneca coordinated by AcademicCME
Session coordinator:
C. Pollack
Summary
Watch this session if you want to understand more about the guidelines for antiplatelet secondary prevention of ACS/PC and to review available data on antiplatelet therapy after ACS/PCI.
Learning Objectives
- To understand more about the guidelines for antiplatelet secondary prevention of ACS/PCI
- To review available data on antiplatelet therapy after ACS/PCI
- To learn about recent trials of antiplatelet therapies in ACS